Company Filing History:
Years Active: 2020-2024
Title: SoHui Kim: Innovator in GPCR Heteromer Inhibitors
Introduction
SoHui Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research through his innovative work on G protein-coupled receptor (GPCR) heteromer inhibitors. With a total of 2 patents, his inventions are paving the way for new therapeutic approaches in oncology.
Latest Patents
One of SoHui Kim's latest patents focuses on GPCR heteromer inhibitors and their uses. This invention pertains to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers associated with cancers. Specifically, it addresses the functional heteromer formed between CXCR4 and other GPCRs, known as GPCRx. The invention highlights how co-stimulation with CXCR4 agonists and GPCRx agonists can enhance signaling downstream of CXCR4. Furthermore, it provides methods for using inhibitors that target the interacting GPCR partner of the CXCR4-GPCRx heteromer, including specific antibodies for diagnosis and therapy in cancer treatment.
Career Highlights
SoHui Kim is currently associated with Gpcr Therapeutics, Inc., where he continues to advance his research in GPCR-related therapies. His work is instrumental in developing innovative solutions for cancer treatment, showcasing his dedication to improving patient outcomes.
Collaborations
SoHui Kim collaborates with notable colleagues, including DongSeung Seen and Eunhee Kim. Their combined expertise contributes to the ongoing research and development efforts at Gpcr Therapeutics, Inc.
Conclusion
SoHui Kim's contributions to the field of GPCR heteromer inhibitors represent a significant advancement in cancer research. His innovative patents and collaborative efforts are set to make a lasting impact on therapeutic strategies for cancer treatment.